just sharing

fast track means in a couple of months if they passed the phase 3 trial in terms of efficacy and safety they could be granted approval..

CEO/CSO has been buying up shares since April 2024 in a sizable amount.

U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved 70% enrollment with completion of enrollment targeted for the end of 2024

Strengthened Board of Directors with election of 3 experienced industry veterans at Annual Meeting

Focused expenditure management reduced first half Total Operating Expenses 22% year-over-year

Financing transaction and warrant exercises in July raised gross proceeds of $15.3 million to fund continued clinical development, and current cash and cash equivalents are expected to be sufficient to fund Company through the fourth quarter of 2025